
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4090942/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. Aids, 1998, 12, F51-F58.	1.0	2,138
2	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. New England Journal of Medicine, 2003, 349, 1993-2003.	13.9	1,560
3	Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. New England Journal of Medicine, 2007, 356, 1723-1735.	13.9	1,393
4	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. Archives of Internal Medicine, 2006, 166, 1632.	4.3	1,004
5	Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection. Journal of Infectious Diseases, 2011, 203, 780-790.	1.9	957
6	Cancer Incidence Before and After Kidney Transplantation. JAMA - Journal of the American Medical Association, 2006, 296, 2823.	3.8	953
7	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, The, 2008, 371, 1417-1426.	6.3	809
8	Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study. Aids, 2003, 17, 1179-1193.	1.0	770
9	Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet, The, 2014, 384, 241-248.	6.3	767
10	Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Antiâ€HIV Drugs (D:A:D) Study. Journal of Infectious Diseases, 2010, 201, 318-330.	1.9	575
11	A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. Aids, 2000, 14, F25-F32.	1.0	538
12	Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology, 2001, 34, 809-816.	3.6	526
13	Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients. Diabetes Care, 2008, 31, 1224-1229.	4.3	448
14	Adjuvant psychological therapy for patients with cancer: a prospective randomised trial BMJ: British Medical Journal, 1992, 304, 675-680.	2.4	438
15	Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. Journal of Hepatology, 2017, 67, 1204-1212.	1.8	390
16	Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. Aids, 2010, 24, 1537-1548.	1.0	381
17	Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study. Journal of Infectious Diseases, 2008, 197, 1133-1144.	1.9	364
18	Cardiovascular disease risk factors in HIV patientsassociation with antiretroviral therapy. Results from the DAD study. Aids, 2003, 17, 1179-93.	1.0	335

#	Article	IF	CITATIONS
19	Relation between HIV viral load and infectiousness: a model-based analysis. Lancet, The, 2008, 372, 314-320.	6.3	324
20	The Mini-MAC. Journal of Psychosocial Oncology, 1994, 12, 33-46.	0.6	312
21	Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug and Alcohol Dependence, 2009, 105, 9-15.	1.6	309
22	Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 491-501.	3.1	309
23	Life expectancy of <scp>HIV</scp> â€positive people after starting combination antiretroviral therapy: a metaâ€analysis. HIV Medicine, 2017, 18, 256-266.	1.0	309
24	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet, The, 2004, 364, 51-62.	6.3	303
25	The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Medicine, 2006, 7, 218-230.	1.0	296
26	Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria: Associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and hypoadiponectinemia. Diabetes Care, 2007, 30, 113-119.	4.3	267
27	Abacavir Substitution for Nucleoside Analogs in Patients With HIV Lipoatrophy <subtitle>A Randomized Trial</subtitle> . JAMA - Journal of the American Medical Association, 2002, 288, 207.	3.8	265
28	Levels of Human Immunodeficiency Virus Type 1 RNA in Cerebrospinal Fluid Correlate with AIDS Dementia Stage. Journal of Infectious Diseases, 1997, 175, 963-966.	1.9	259
29	Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nature Medicine, 2009, 15, 285-292.	15.2	259
30	Hepatitis Bâ€related hepatocellular carcinoma: epidemiological characteristics and disease burden. Journal of Viral Hepatitis, 2009, 16, 453-463.	1.0	252
31	No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet, The, 2004, 363, 429-438.	6.3	241
32	Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet, The, 2006, 368, 938-945.	6.3	237
33	Surgical treatment and risk of sporadic Creutzfeldt-Jakob disease: a case-control study. Lancet, The, 1999, 353, 693-697.	6.3	231
34	Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. Aids, 2010, 24, 907-913.	1.0	228
35	Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. Aids, 2002, 16, 1155-1161.	1.0	207
36	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. Aids, 2008, 22, 2143-2153.	1.0	207

#	Article	IF	CITATIONS
37	An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. European Journal of Preventive Cardiology, 2016, 23, 214-223.	0.8	180
38	Risk of cancer in people with AIDS. Aids, 1999, 13, 839-843.	1.0	176
39	Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2018, 3, 754-767.	3.7	174
40	Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. Aids, 2007, 21, 2315-2321.	1.0	172
41	Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. Aids, 2007, 21, 2445-2453.	1.0	163
42	Epidemiology of hepatitis C virus infection in Australia. Journal of Clinical Virology, 2003, 26, 171-184.	1.6	162
43	HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. Aids, 2001, 15, 1811-1822.	1.0	155
44	Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV,the, 2018, 5, e291-e300.	2.1	155
45	Extreme cause-specific mortality in a cohort of adult prisoners—1988 to 2002: a data-linkage study. International Journal of Epidemiology, 2007, 36, 310-316.	0.9	154
46	The TREAT Asia HIV Observational Database. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 174-179.	0.9	151
47	Cancer incidence in people with hepatitis B or C infection: A large community-based linkage study. Journal of Hepatology, 2006, 45, 197-203.	1.8	142
48	Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. Aids, 2001, 15, 629-633.	1.0	141
49	Importance of promoting HIV testing for preventing secondary transmissions: modelling the Australian HIV epidemic among men who have sex with men. Sexual Health, 2009, 6, 19.	0.4	141
50	How many dependent heroin users are there in Australia?. Medical Journal of Australia, 2000, 173, 528-531.	0.8	133
51	Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. International Journal of Epidemiology, 2003, 32, 717-724.	0.9	129
52	The Coding Causes of Death in HIV (CoDe) Project. Epidemiology, 2011, 22, 516-523.	1.2	129
53	B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. Aids, 2000, 14, 133-140.	1.0	125
54	Hormonal Contraception Is Associated with a Reduced Risk of Bacterial Vaginosis: A Systematic Review and Meta-Analysis. PLoS ONE, 2013, 8, e73055.	1.1	124

#	Article	IF	CITATIONS
55	Shortâ€ŧerm weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the <scp>D</scp> : <scp>A</scp> : <scp>D</scp> study. HIV Medicine, 2016, 17, 255-268.	1.0	122
56	Effect of availability of HIV self-testing on HIV testing frequency in gay and bisexual men at high risk of infection (FORTH): a waiting-list randomised controlled trial. Lancet HIV,the, 2017, 4, e241-e250.	2.1	120
57	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. PLoS Medicine, 2015, 12, e1001809.	3.9	119
58	Modelling the hepatitis C virus epidemic in Australia. Drug and Alcohol Dependence, 2007, 91, 228-235.	1.6	117
59	Recurrence of Bacterial Vaginosis Is Significantly Associated With Posttreatment Sexual Activities and Hormonal Contraceptive Use. Clinical Infectious Diseases, 2013, 56, 777-786.	2.9	117
60	Modelling the effect of combination antiretroviral treatments on HIV incidence. Aids, 2001, 15, 1287-1294.	1.0	114
61	Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. Aids, 2009, 23, 2183-2190.	1.0	108
62	Adjuvant psychological therapy for patients with cancer: Outcome at one year. Psycho-Oncology, 1994, 3, 39-46.	1.0	106
63	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clinical Infectious Diseases, 2018, 66, 893-903.	2.9	105
64	Factors associated with mortality in a cohort of Australian prisoners. European Journal of Epidemiology, 2007, 22, 417-428.	2.5	103
65	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology, 2020, 72, 643-657.	1.8	103
66	Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. Antiviral Therapy, 2005, 10, 811-823.	0.6	103
67	Suicide risk among recently released prisoners in New South Wales, Australia. Medical Journal of Australia, 2007, 187, 387-390.	0.8	102
68	Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Medicine, 2016, 14, 61.	2.3	100
69	Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: A meta-analysis of six prospective, randomized, comparative studies. Clinical Therapeutics, 2004, 26, 92-97.	1.1	97
70	Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrology Dialysis Transplantation, 2012, 27, 70-75.	0.4	96
71	A comparison of adjuvant psychological therapy and supportive counselling in patients with cancer. , 1998, 7, 218-228.		95
72	Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database. Journal of the International AIDS Society, 2012, 15, 1-1.	1.2	92

#	Article	IF	CITATIONS
73	Rising incidence of oesophageal adenocarcinoma in men in Australia. Journal of Gastroenterology and Hepatology (Australia), 1998, 13, 356-362.	1.4	91
74	Estimates of chronic hepatitis B virus infection in Australia, 2000. Australian and New Zealand Journal of Public Health, 2004, 28, 212-216.	0.8	89
75	Trends in anal cancer in Australia, 1982–2005. Vaccine, 2011, 29, 2322-2327.	1.7	89
76	Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus. Circulation, 2009, 119, 805-811.	1.6	88
77	Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. Radiotherapy and Oncology, 1997, 42, 121-135.	0.3	87
78	Effectiveness of needle and syringe programmes for preventing HIV transmission. International Journal of Drug Policy, 2003, 14, 353-357.	1.6	87
79	Patterns of Viral Dynamics during Primary Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 1998, 178, 1812-1815.	1.9	85
80	Planned and unplanned gaps in radiotherapy: the importance of gap position and gap duration. Radiotherapy and Oncology, 1994, 30, 109-120.	0.3	84
81	A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. Aids, 2002, 16, 2195-2200.	1.0	82
82	Is severe liver disease a common outcome for people with chronic hepatitisC?. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 423-430.	1.4	82
83	Predicting progression to cirrhosis in chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2003, 10, 285-293.	1.0	82
84	An Objective Lipodystrophy Severity Grading Scale Derived From the Lipodystrophy Case Definition Score. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 571-576.	0.9	82
85	Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction, 2009, 104, 1363-1372.	1.7	81
86	The influence of sexual activity on the vaginal microbiota and Gardnerella vaginalis clade diversity in young women. PLoS ONE, 2017, 12, e0171856.	1.1	81
87	Estimating the cost-effectiveness of needle-syringe programs in Australia. Aids, 2012, 26, 2201-2210.	1.0	79
88	Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infectious Diseases, The, 2012, 12, 933-941.	4.6	78
89	A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. Aids, 2000, 14, 1171-1180.	1.0	76
90	Predictors of recent HIV testing in homosexual men in Australia. HIV Medicine, 2002, 3, 271-276.	1.0	76

#	Article	IF	CITATIONS
91	Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. Journal of Hepatology, 2019, 71, 281-288.	1.8	76
92	Global burden of transmitted HIV drug resistance and HIV-exposure categories. Aids, 2014, 28, 2751-2762.	1.0	75
93	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. American Journal of Epidemiology, 2019, 188, 1569-1577.	1.6	75
94	Spinal cord compression in prostate cancer: treatment outcome and prognostic factors. Radiotherapy and Oncology, 1997, 44, 229-236.	0.3	71
95	Primary hepatocellular carcinoma in Australia, 1978â€1997: increasing incidence and mortality. Medical Journal of Australia, 2000, 173, 403-405.	0.8	71
96	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. BMC Infectious Diseases, 2013, 13, 471.	1.3	68
97	The Influence of Behaviors and Relationships on the Vaginal Microbiota of Women and Their Female Partners: The WOW Health Study. Journal of Infectious Diseases, 2014, 209, 1562-1572.	1.9	68
98	A Randomized, Controlled, Phase II Trial Comparing Escalating Doses of Subcutaneous Interleukinâ€2 plus Antiretrovirals versus Antiretrovirals Alone in Human Immunodeficiency Virus–Infected Patients with CD4+Cell Counts ⩾350/mm3. Journal of Infectious Diseases, 2000, 181, 1614-1621.	1.9	67
99	Incident Bacterial Vaginosis (BV) in Women Who Have Sex With Women Is Associated With Behaviors That Suggest Sexual Transmission of BV. Clinical Infectious Diseases, 2015, 60, 1042-1053.	2.9	67
100	Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. Aids, 2010, 24, 1877-1886.	1.0	66
101	Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. British Journal of Cancer, 1994, 69, 1052-1058.	2.9	65
102	An enormous hepatitis B virusâ€related liver disease burden projected in Vietnam by 2025. Liver International, 2008, 28, 525-531.	1.9	65
103	The Impact of Needle and Syringe Programs on HIV and HCV Transmissions in Injecting Drug Users in Australia: A Model-Based Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 462-469.	0.9	65
104	The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection. Journal of Hepatology, 2003, 38, 349-356.	1.8	64
105	Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy. PLoS ONE, 2012, 7, e48839.	1.1	63
106	Population effectiveness of opportunistic chlamydia testing in primary care in Australia: a cluster-randomised controlled trial. Lancet, The, 2018, 392, 1413-1422.	6.3	63
107	The cascade of HIV care among key populations in Indonesia: a prospective cohort study. Lancet HIV,the, 2018, 5, e560-e568.	2.1	63
108	Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. Aids, 2014, 28, 187-199.	1.0	60

#	Article	IF	CITATIONS
109	Urine Flow Rates and Residual Urine Volumes in Urogynecology Patients. International Urogynecology Journal, 1999, 10, 378-383.	0.7	59
110	Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection. Aids, 2000, 14, 197-201.	1.0	59
111	Mucosally-administered human–simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine, 2005, 23, 5009-5021.	1.7	59
112	HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy—Results From the IeDEA Collaboration. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 319-329.	0.9	58
113	The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. Journal of Hepatology, 2018, 68, 393-401.	1.8	58
114	Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). Journal of the American Academy of Dermatology, 2014, 70, 89-97.e13.	0.6	57
115	The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations, 1997–2006. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1648-1654.	1.4	56
116	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. Clinical Infectious Diseases, 2013, 57, 112-121.	2.9	56
117	Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infectious Diseases, The, 2015, 15, 1314-1323.	4.6	56
118	Mortality and losses to followâ€up among adolescents living with HIV in the Ie DEA global cohort collaboration. Journal of the International AIDS Society, 2018, 21, e25215.	1.2	56
119	Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipidâ€Lowering Drugs in HIVâ€Infected Individuals and Impact on Myocardial Infarction. Clinical Infectious Diseases, 2008, 46, 1101-1110.	2.9	55
120	Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Journal of the International AIDS Society, 2012, 15, 17426.	1.2	54
121	Estimating the critical immunity threshold for preventing hepatitis A outbreaks in men who have sex with men. Epidemiology and Infection, 2016, 144, 1528-1537.	1.0	54
122	Modelling the hepatitis C virus epidemic in Australia. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 1100-1107.	1.4	53
123	Immediate Postvoid Residual Volumes in Women With Symptoms of Pelvic Floor Dysfunction. Obstetrics and Gynecology, 2008, 111, 1305-1312.	1.2	52
124	Estimated mortality of adult HIV-infected patients starting treatment with combination antiretroviral therapy. Sexually Transmitted Infections, 2012, 88, i33-i43.	0.8	52
125	Serum Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15): A Potential Screening Tool for the Prevention of Colon Cancer?. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 337-346.	1.1	52
126	The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. International Journal of Epidemiology, 2003, 32, 708-714.	0.9	51

#	Article	IF	CITATIONS
127	Increasing cancer mortality among opioidâ€dependent persons in Australia: a new public health challenge for a disadvantaged population. Australian and New Zealand Journal of Public Health, 2011, 35, 220-225.	0.8	51
128	Associations between immune depression and cardiovascular events in HIV infection. Aids, 2013, 27, 2735-2748.	1.0	51
129	Buffalo Hump Seen in HIV-Associated Lipodystrophy is Associated With Hyperinsulinemia But Not Dyslipidemia. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 156-162.	0.9	50
130	Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons. Aids, 2016, 30, 1731-1743.	1.0	50
131	The role of initial AIDS-defining illness in survival following AIDS. Aids, 1995, 9, 57-64.	1.0	49
132	HIV disease progression in Australia in the time of combination antiretroviral therapies. Medical Journal of Australia, 1998, 169, 469-472.	0.8	49
133	Dynamics of T Cells and TCR Excision Circles Differ After Treatment of Acute and Chronic HIV Infection. Journal of Immunology, 2002, 169, 4657-4666.	0.4	49
134	Intensity of human prion disease surveillance predicts observed disease incidence. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1372-1377.	0.9	49
135	Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy. Aids, 2003, 17, 1094-1096.	1.0	49
136	CD8+ Lymphocyte Responses to Antiretroviral Therapy of HIV Infection. Journal of Acquired Immune Deficiency Syndromes, 1996, 13, 320-326.	0.3	49
137	Has the true prevalence of voiding difficulty in urogynecology patients been underestimated?. International Urogynecology Journal, 2007, 18, 53-56.	0.7	48
138	Counting the cost: estimating the number of deaths among recently released prisoners in Australia. Medical Journal of Australia, 2011, 195, 64-68.	0.8	48
139	Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN? or IL-12. Vaccine, 2004, 23, 188-197.	1.7	47
140	Is sensory urgency part of the same spectrum of bladder dysfunction as detrusor overactivity?. International Urogynecology Journal, 2006, 18, 123-128.	0.7	47
141	Back-projection estimates of the number of dependent heroin users in Australia. Addiction, 2001, 96, 433-443.	1.7	46
142	Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Medicine, 2007, 8, 8-16.	1.0	46
143	Control of Viremia and Prevention of AIDS following Immunotherapy of SIV-Infected Macaques with Peptide-Pulsed Blood. PLoS Pathogens, 2008, 4, e1000055.	2.1	46
144	Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sexual Health, 2007, 4, 147.	0.4	46

#	Article	IF	CITATIONS
145	Lipodystrophy following antiretroviral therapy of primary HIV infection. Aids, 2000, 14, 2406-2407.	1.0	46
146	Accuracy of pelvic radiotherapy: prospective analysis of 90 patients in a randomised trial of blocked versus standard radiotherapy. Radiotherapy and Oncology, 1996, 39, 19-29.	0.3	45
147	Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study. HIV Clinical Trials, 2002, 3, 177-185.	2.0	45
148	Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006. Journal of Hepatology, 2011, 54, 879-886.	1.8	45
149	Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. PLoS ONE, 2015, 10, e0139981.	1.1	45
150	Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1757-1764.	1.4	44
151	Increased risk of cardiovascular disease (<scp>CVD</scp>) with age in <scp>HIV</scp> â€positive men: a comparison of the <scp>D</scp> : <scp>A</scp> : <scp>D CVD</scp> risk equation and general population < <scp>CVD</scp> risk equations. HIV Medicine, 2014, 15, 595-603.	1.0	44
152	A multicentre double-blind randomised controlled trial evaluating the efficacy of daily use of antibacterial mouthwash against oropharyngeal gonorrhoea among men who have sex with men: the OMEGA (Oral Mouthwash use to Eradicate GonorrhoeA) study protocol. BMC Infectious Diseases, 2017, 17, 456.	1.3	44
153	Testing Commercial Sex Workers for Sexually Transmitted Infections in Victoria, Australia: An Evaluation of the Impact of Reducing the Frequency of Testing. PLoS ONE, 2014, 9, e103081.	1.1	44
154	Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antiviral Therapy, 2005, 10, 811-23.	0.6	43
155	Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Medical Journal of Australia, 2011, 194, 398-402.	0.8	42
156	HIV-1 Drug Resistance Mutations Among Antiretroviral-Naive HIV-1-Infected Patients in Asia: Results From the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clinical Infectious Diseases, 2011, 52, 1053-1057.	2.9	42
157	Azithromycin or Doxycycline for Asymptomatic Rectal <i>Chlamydia trachomatis</i> . New England Journal of Medicine, 2021, 384, 2418-2427.	13.9	42
158	Rapidly ageing HIV epidemic among men who have sex with men in Australia. Sexual Health, 2009, 6, 83.	0.4	42
159	Expression of 2 variant forms of fibroblast growth factor receptor 1 in human breast. International Journal of Cancer, 1995, 64, 274-279.	2.3	41
160	Long-Term Patterns in CD4 Response Are Determined by an Interaction Between Baseline CD4 Cell Count, Viral Load, and Time: The Asia Pacific HIV Observational Database (APHOD). Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 513-520.	0.9	41
161	Near Elimination of Genital Warts in Australia Predicted With Extension of Human Papillomavirus Vaccination to Males. Sexually Transmitted Diseases, 2013, 40, 833-835.	0.8	41
162	Site-specific human papillomavirus infection in adolescent men who have sex with men (HYPER): an observational cohort study. Lancet Infectious Diseases, The, 2015, 15, 65-73.	4.6	40

#	Article	IF	CITATIONS
163	Smoking, alcohol and illicit drug use effects on survival in HIV-positive persons. Current Opinion in HIV and AIDS, 2016, 11, 514-520.	1.5	40
164	Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival. PLoS ONE, 2016, 11, e0150512.	1.1	40
165	Factors Associated with Bacterial Vaginosis among Women Who Have Sex with Women: A Systematic Review. PLoS ONE, 2015, 10, e0141905.	1.1	39
166	Antiretroviral Therapy Outcomes of HIV-Infected Children in the TREAT Asia Pediatric HIV Observational Database. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 503-509.	0.9	38
167	Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective. Vaccine, 2017, 35, 4923-4929.	1.7	38
168	Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D:A:D Cohort Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 579-588.	0.9	38
169	Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries. Lancet HIV,the, 2021, 8, e766-e775.	2.1	38
170	Primary Infection with Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Does Not Adversely Affect Outcome at 1 Year. Journal of Infectious Diseases, 1996, 174, 195-198.	1.9	37
171	Vaccine-induced IgC2 anti-HIV p24 is associated with control of HIV in patients with a â€ ⁻ high-affinity' FcγRIIa genotype. Aids, 2010, 24, 1983-1990.	1.0	37
172	Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment. Journal of Hepatology, 2015, 62, 269-277.	1.8	36
173	Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014). Journal of Hepatology, 2016, 65, 1086-1093.	1.8	36
174	Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals. Scientific Reports, 2017, 7, 10934.	1.6	36
175	Increased Incidence of Squamous Cell Carcinoma of Eye After Kidney Transplantation. Journal of the National Cancer Institute, 2007, 99, 1340-1342.	3.0	35
176	TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. Journal of Virological Methods, 2009, 159, 185-193.	1.0	35
177	HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. Antiviral Therapy, 2010, 15, 1077-1086.	0.6	35
178	Shortâ€ŧerm risk of anaemia following initiation of combination antiretroviral treatment in HIVâ€infected patients in countries in sub‣aharan Africa, Asiaâ€Pacific, and central and South America. Journal of the International AIDS Society, 2012, 15, 5-5.	1.2	34
179	Factors associated with suboptimal adherence to antiretroviral therapy in Asia. Journal of the International AIDS Society, 2014, 17, 18911.	1.2	34
180	Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study. Journal of Infectious Diseases, 2016, 214, 1212-1220.	1.9	34

#	Article	IF	CITATIONS
181	The potential impact of new generation molecular point-of-care tests on gonorrhoea and chlamydia in a setting of high endemic prevalence. Sexual Health, 2013, 10, 348.	0.4	34
182	Clinical Predictors of Immune Reconstitution following Combination Antiretroviral Therapy in Patients from the Australian HIV Observational Database. PLoS ONE, 2011, 6, e20713.	1.1	34
183	Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia. HIV Medicine, 2004, 5, 377-384.	1.0	33
184	Mortality among prisoners: how accurate is the Australian National Death Index?. Australian and New Zealand Journal of Public Health, 2005, 29, 572-575.	0.8	33
185	Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals: Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study. Diabetes Care, 2009, 32, 474-480.	4.3	33
186	Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 1993, 44, 583-587.	1.2	32
187	Therapeutic Vaccination with p24-VLP and Zidovudine Augments HIV-Specific Cytotoxic T Lymphocyte Activity in Asymptomatic HIV-Infected Individuals. AIDS Research and Human Retroviruses, 1999, 15, 105-113.	0.5	32
188	AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. Aids, 2009, 23, 2323-2336.	1.0	32
189	Reproducibility of adenosine stress cardiovascular magnetic resonance in multi-vessel symptomatic coronary artery disease. Journal of Cardiovascular Magnetic Resonance, 2010, 12, 42.	1.6	32
190	A pilot comparison study of four clinicianâ€rated atopic dermatitis severity scales. British Journal of Dermatology, 2015, 173, 488-497.	1.4	32
191	Prospective Analysis of Seizures Occurring in Human Immunodeficiency Virus Type-1 Infection. Journal of Neuro-AIDS, 1997, 1, 59-69.	0.2	31
192	Changes in Body Composition and Mitochondrial Nucleic Acid Content in Patients Switched from Failed Nucleoside Analogue Therapy to Ritonavirâ€Boosted Indinavir and Efavirenz. Journal of Infectious Diseases, 2006, 194, 642-650.	1.9	31
193	Chlamydia prevalence in young attenders of rural and regional primary care services in Australia: a crossâ€sectional survey. Medical Journal of Australia, 2014, 200, 170-175.	0.8	31
194	Liver cancer and hepatitis B and C in New South Wales, 1990–2002: a linkage study. Australian and New Zealand Journal of Public Health, 2007, 31, 475-482.	0.8	30
195	Recurrent urinary tract infections in women with symptoms of pelvic floor dysfunction. International Urogynecology Journal, 2009, 20, 837-842.	0.7	30
196	Loss to Followup in HIV-Infected Patients from Asia-Pacific Region: Results from TAHOD. AIDS Research and Treatment, 2012, 2012, 1-10.	0.3	30
197	Cancer Incidence in a Nationwide HIV/AIDS Patient Cohort in Taiwan in 1998–2009. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 463-472.	0.9	30
198	The reliability and validity of outcome measures for atopic dermatitis in patients with pigmented skin: A grey area. International Journal of Women's Dermatology, 2015, 1, 150-154.	1.1	30

#	Article	IF	CITATIONS
199	Predictors of Progression in Long-Term Nonprogressors. AIDS Research and Human Retroviruses, 1998, 14, 117-121.	0.5	29
200	Randomised, Placebo-Controlled, Phase I/IIa Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-? in HIV-1 Infected Subjects. Hum Vaccin, 2005, 1, 232-238.	2.4	29
201	HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. Aids, 2005, 19, 169-178.	1.0	29
202	Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based study. Journal of Hepatology, 2016, 65, 879-887.	1.8	29
203	Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning. Addiction, 2009, 104, 2049-2056.	1.7	28
204	Cancers in the TREAT Asia HIV Observational Database (TAHOD): a retrospective analysis of risk factors. Journal of the International AIDS Society, 2010, 13, 51-51.	1.2	28
205	Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a populationâ€based cohort study, 1992–2007. Journal of Viral Hepatitis, 2011, 18, e232-41.	1.0	28
206	Trends in detectable viral load by calendar year in the Australian HIV observational database. Journal of the International AIDS Society, 2011, 14, 10-10.	1.2	28
207	Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years—The Australian Positive & Peers Longevity Evaluation Study (APPLES). PLoS ONE, 2017, 12, e0184583.	1.1	28
208	Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. Lancet HIV,the, 2018, 5, e172-e180.	2.1	28
209	The CpG Island Methylator Phenotype Is Not Associated with a Personal or Family History of Cancer. Cancer Research, 2004, 64, 7618-7621.	0.4	27
210	Modeling Trends in HIV Incidence Among Homosexual Men in Australia 1995???2006. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 35, 401-406.	0.9	27
211	Hepatitis C treatment outcomes in Australian clinics. Medical Journal of Australia, 2012, 196, 633-637.	0.8	27
212	High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. Journal of Hepatology, 2021, 74, 293-302.	1.8	27
213	Determinants of Suicide and Accidental or Violent Death in the Australian HIV Observational Database. PLoS ONE, 2014, 9, e89089.	1.1	27
214	A New Method for Assessing How Sensitivity and Specificity of Linkage Studies Affects Estimation. PLoS ONE, 2014, 9, e103690.	1.1	27
215	Difference in Absolute CD4+ Count According to CD4 Percentage between Asian and Caucasian HIV-Infected Patients. Journal of AIDS & Clinical Research, 2010, 01, 1-4.	0.5	27
216	The Role of Hydroxyurea in Enhancing the Virologic Control Achieved Through Structured Treatment Interruption in Primary HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 192-202.	0.9	26

#	Article	IF	CITATIONS
217	A Randomised Trial Comparing Genotypic and Virtual Phenotypic Interpretation of HIV Drug Resistance: The CREST Study. PLOS Clinical Trials, 2006, 1, e18.	3.5	26
218	Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD). AIDS Research and Therapy, 2007, 4, 18.	0.7	26
219	Estimates and projections of hepatitis Bâ€related hepatocellular carcinoma in Australia among people born in Asiaâ€Pacific countries. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 922-929.	1.4	26
220	STI in remote communities: improved and enhanced primary health care (STRIVE) study protocol: a cluster randomised controlled trial comparing †usual practice' STI care to enhanced care in remote primary health care services in Australia. BMC Infectious Diseases, 2013, 13, 425.	1.3	26
221	Eradicating syphilis, hepatitis C and HIV in MSM through frequent testing strategies. Current Opinion in Infectious Diseases, 2014, 27, 56-61.	1.3	26
222	All-cause mortality in HIV-positive adults starting combination antiretroviral therapy. Aids, 2017, 31, S31-S40.	1.0	26
223	Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 562-571.	0.9	26
224	Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment. Sexual Health, 2008, 5, 141.	0.4	26
225	Impact of Early HIV-1 RNA and T-Lymphocyte Dynamics During Primary HIV-1 Infection on the Subsequent Course of HIV-1 RNA Levels and CD4+ T-Lymphocyte Counts in the First Year of HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 437.	0.9	25
226	Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies. Vox Sanguinis, 2001, 81, 6-11.	0.7	25
227	Influence of IFNÎ ³ Co-Expression on the Safety and Antiviral Efficacy of Recombinant Fowlpox Virus HIV Therapeutic Vaccines Following Interruption of Antiretroviral Therapy. Hum Vaccin, 2007, 3, 260-267.	2.4	25
228	Enhanced geographically restricted surveillance simulates sporadic Creutzfeldt-Jakob disease cluster. Brain, 2009, 132, 493-501.	3.7	25
229	Shortâ€Term Clinical Disease Progression in HIVâ€Infected Patients Receiving Combination Antiretroviral Therapy: Results from the TREAT Asia HIV Observational Database. Clinical Infectious Diseases, 2009, 48, 940-950.	2.9	25
230	Characterizing trends in HIV infection among men who have sex with men in Australia by birth cohorts: results from a modified backâ€projection method. Journal of the International AIDS Society, 2009, 12, 19-19.	1.2	25
231	Evaluation of the HIV Lipodystrophy Case Definition in a Placebo-Controlled, 144-Week Study in Antiretroviral-Naive Adults. Antiviral Therapy, 2006, 11, 179-186.	0.6	25
232	Cancer, immunodeficiency and antiretroviral treatment: results from the Australian <scp>HIV O</scp> bservational <scp>D</scp> atabase (<scp>AHOD</scp>). HIV Medicine, 2013, 14, 77-84.	1.0	24
233	Efficacy of Second-Line Antiretroviral Therapy Among People Living With HIV/AIDS in Asia. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 186-195.	0.9	24
234	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 240-250.	0.9	24

#	Article	IF	CITATIONS
235	Antiseptic mouthwash for gonorrhoea prevention (OMEGA): a randomised, double-blind, parallel-group, multicentre trial. Lancet Infectious Diseases, The, 2021, 21, 647-656.	4.6	24
236	Effect of Transient Antiretroviral Treatment during acute HIV Infection: Comparison of the Quest Trial Results with CASCADE Natural History Study. Antiviral Therapy, 2007, 12, 189-194.	0.6	24
237	Estimation of Risk of Cancers before Occurrence of Acquired Immunodeficiency Syndrome in Persons Infected with Human Immunodeficiency Virus. American Journal of Epidemiology, 2002, 155, 153-158.	1.6	23
238	Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiology and Infection, 2007, 135, 144-150.	1.0	23
239	Life Expectancy after Initiation of Combination Antiretroviral Therapy in Thailand. Antiviral Therapy, 2017, 22, 393-402.	0.6	23
240	Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression. Lancet HIV,the, 2022, 9, e414-e427.	2.1	23
241	AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment. Aids, 1999, 13, 263-269.	1.0	22
242	Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD). HIV Medicine, 2010, 11, 31-39.	1.0	22
243	Hospitalizations in a cohort of HIV patients in Australia, 1999–2007. Aids, 2010, 24, 1329-1339.	1.0	22
244	Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database. BMC Infectious Diseases, 2010, 10, 361.	1.3	22
245	Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. BMC Infectious Diseases, 2018, 18, 215.	1.3	22
246	Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial. Scientific Reports, 2019, 9, 3555.	1.6	22
247	Sexual practices have a significant impact on the vaginal microbiota of women who have sex with women. Scientific Reports, 2019, 9, 19749.	1.6	22
248	Risk factors and causes of death in the Australian HIV Observational Database. Sexual Health, 2006, 3, 103.	0.4	22
249	The safety of candidate vaginal microbicides since nonoxynol-9: a systematic review of published studies. Aids, 2009, 23, 1245-1254.	1.0	21
250	The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. Aids, 2016, 30, 2659-2663.	1.0	21
251	Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus–infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Clinical Infectious Diseases, 2019, 68, 650-657.	2.9	21
252	Hidden Drug Resistant HIV to Emerge in the Era of Universal Treatment Access in Southeast Asia. PLoS ONE, 2010, 5, e10981.	1.1	20

#	Article	IF	CITATIONS
253	Impact of Antiretroviral Therapy on Opportunistic Infections of HIV-infected Children in the Therapeutic Research, Education and AIDS Training Asia Pediatric HIV Observational Database. Pediatric Infectious Disease Journal, 2014, 33, 747-752.	1.1	20
254	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Open Forum Infectious Diseases, 2016, 3, ofw009.	0.4	20
255	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	2.9	20
256	Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study. Antiviral Therapy, 2016, 21, 495-506.	0.6	20
257	Loss to Follow-up Trends in HIV-Positive Patients Receiving Antiretroviral Treatment in Asia From 2003 to 2013. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 555-562.	0.9	20
258	Estimating the number of people who inject drugs and syringe coverage in Australia, 2005–2016. Drug and Alcohol Dependence, 2019, 197, 108-114.	1.6	20
259	Incidence and time trends of anal cancer among people living with HIV in Australia. Aids, 2019, 33, 1361-1368.	1.0	20
260	SURVIVAL ANALYSES OF RANDOMIZED CLINICAL TRIALS ADJUSTED FOR PATIENTS WHO SWITCH TREATMENTS. , 1996, 15, 2069-2076.		19
261	Impact of Early HIV-1 RNA and T-Lymphocyte Dynamics During Primary HIV-1 Infection on the Subsequent Course of HIV-1 RNA Levels and CD4+ T-Lymphocyte Counts in the First Year of HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 437.	0.9	19
262	Using mathematical modelling to help explain the differential increase in HIV incidence in New South Wales, Victoria and Queensland: importance of other sexually transmissible infections. Sexual Health, 2008, 5, 169.	0.4	19
263	Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD). Endocrine Journal, 2011, 58, 475-484.	0.7	19
264	Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. Journal of Viral Hepatitis, 2018, 25, 473-481.	1.0	19
265	Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2018, 5, e553-e559.	2.1	19
266	Natural History Models for Hepatitis C-Related Liver Disease: Different Disease Progression Parameters for Different Settings. Antiviral Therapy, 2003, 8, 365-372.	0.6	19
267	Mortality rates among nuclear industry workers at Lucas Heights Science and Technology Centre. Australian and New Zealand Journal of Public Health, 2005, 29, 229-237.	0.8	18
268	Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings. Aids, 2011, 25, 1143-1151.	1.0	18
269	Increased mortality among Indigenous persons during and after release from prison in New South Wales. Australian and New Zealand Journal of Public Health, 2012, 36, 274-280.	0.8	18
270	Ageing and longâ€ŧerm <scp>CD</scp> 4 cell count trends in <scp>HIV</scp> â€positive patients with 5 years or more combination antiretroviral therapy experience. HIV Medicine, 2013, 14, 208-216.	1.0	18

#	Article	IF	CITATIONS
271	Trends in First-Line Antiretroviral Therapy in Asia: Results from the TREAT Asia HIV Observational Database. PLoS ONE, 2014, 9, e106525.	1.1	18
272	Innovations in health and demographic surveillance systems to establish the causal impacts of HIV policies. Current Opinion in HIV and AIDS, 2015, 10, 483-494.	1.5	18
273	Improved Survival in HIV Treatment Programmes in Asia. Antiviral Therapy, 2016, 21, 517-527.	0.6	18
274	Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control. Aids, 2002, 16, 2489-2491.	1.0	18
275	Changes in Biologic Phenotype of Human Immunodeficiency Virus during Treatment of Patients with Didanosine. Journal of Infectious Diseases, 1996, 173, 1092-1096.	1.9	17
276	The Safety, Efficacy, and Pharmacokinetic Profile of a Switch in Antiretroviral Therapy to Saquinavir, Ritonavir, and Atazanavir Alone for 48 Weeks and a Switch in the Saquinavir Formulation. Clinical Infectious Diseases, 2007, 44, 1475-1483.	2.9	17
277	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. PLoS Medicine, 2017, 14, e1002424.	3.9	17
278	Concordance of gonorrhoea of the rectum, pharynx and urethra in same-sex male partnerships attending a sexual health service in Melbourne, Australia. BMC Infectious Diseases, 2018, 18, 95.	1.3	17
279	Findings from Integrated Behavioral and Biologic Survey among Males Who Inject Drugs (MWID) — Vietnam, 2009–2010: Evidence of the Need for an Integrated Response to HIV, Hepatitis B Virus, and Hepatitis C Virus. PLoS ONE, 2015, 10, e0118304.	1.1	17
280	The cost of hepatitis C and the cost–effectiveness of its prevention. Health Policy, 2001, 58, 121-131.	1.4	16
281	Granulocyte colony stimulating factor in chronic angina to stimulate neovascularisation: a placebo controlled crossover trial. Heart, 2012, 98, 282-290.	1.2	16
282	Population movement can sustain STI prevalence in remote Australian indigenous communities. BMC Infectious Diseases, 2013, 13, 188.	1.3	16
283	Evaluating Immunologic Response and Clinical Deterioration in Treatment-Naive Patients Initiating First-Line Therapies Infected With HIV–1 CRF01_AE and Subtype B. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 293-300.	0.9	16
284	Loss to follow-up in the Australian HIV Observational Database. Antiviral Therapy, 2015, 20, 731-741.	0.6	16
285	CD4:CD8 Ratio Comparison between Cohorts of HIV-Positive Asians and Caucasians upon Commencement of Antiretroviral Therapy. Antiviral Therapy, 2017, 22, 659-668.	0.6	16
286	Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals. Aids, 2017, 31, 1261-1270.	1.0	16
287	Comprehensiveness of HIV care provided at global HIV treatment sites in the IeDEA consortium: 2009 and 2014. Journal of the International AIDS Society, 2017, 20, 20933.	1.2	16
288	Rates of pelvic inflammatory disease and ectopic pregnancy in Australia, 2009–2014: ecological analysis of hospital data. Sexually Transmitted Infections, 2018, 94, 534-541.	0.8	16

#	Article	IF	CITATIONS
289	Sexâ€based differences in antiretroviral therapy initiation, switching and treatment interruptions: global overview from the International Epidemiologic Databases to Evaluate AIDS (IeDEA). Journal of the International AIDS Society, 2018, 21, e25149.	1.2	16
290	Effect of Changes in Body Mass Index on the Risk of Cardiovascular Disease and Diabetes Mellitus in HIV-Positive Individuals: Results From the D:A:D Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 579-586.	0.9	16
291	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment–Experienced People Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, e2323-e2333.	2.9	16
292	Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. HIV Medicine, 2022, 23, 895-910.	1.0	16
293	Association between HIV distal symmetric polyneuropathy and Mycobacterium avium complex infection Journal of Neurology, Neurosurgery and Psychiatry, 1996, 61, 606-609.	0.9	15
294	Cancer Incidence among Australian Nuclear Industry Workers. Journal of Occupational Health, 2006, 48, 358-365.	1.0	15
295	Modelling and calibration of the hepatitis C epidemic in Australia. Statistical Methods in Medical Research, 2009, 18, 253-270.	0.7	15
296	Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study. BMC Public Health, 2011, 11, 52.	1.2	15
297	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, e85-e92.	0.9	15
298	High hepatitis C virus (HCV) prevalence among men who have sex with men (MSM) in Vietnam and associated risk factors: 2010 Vietnam Integrated Behavioural and Biologic Cross-Sectional Survey. Sexually Transmitted Infections, 2016, 92, 542-549.	0.8	15
299	High HIV Prevalence and Risk Among Male Clients of Female Sex Workers in Hanoi and Ho Chi Minh City, Vietnam. AIDS and Behavior, 2017, 21, 2381-2393.	1.4	15
300	Abacavir use and risk of recurrent myocardial infarction. Aids, 2018, 32, 79-88.	1.0	15
301	Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. EClinicalMedicine, 2019, 13, 91-100.	3.2	15
302	Changes in mortality following HIV and AIDS and estimation of the number of people living with diagnosed HIV/AIDS in Australia, 1981 - 2003. Sexual Health, 2009, 6, 129.	0.4	15
303	Estimates of chronic hepatitis B virus infection in Australia, 2000. Australian and New Zealand Journal of Public Health, 2004, 28, 212-216.	0.8	15
304	Progression of Lipodystrophy (LD) with Continued Thymidine Analogue Usage: Long-Term Follow-Up from a Randomized Clinical Trial (The PIILR Study). HIV Clinical Trials, 2004, 5, 192-200.	2.0	14
305	Hospital-related morbidity in people notified with hepatitis C: A population-based record linkage study in New South Wales, Australia. Journal of Hepatology, 2010, 53, 43-49.	1.8	14
306	The chlamydia knowledge, awareness and testing practices of Australian general practitioners and practice nurses: survey findings from the Australian Chlamydia Control Effectiveness Pilot (ACCEPt). BMC Family Practice, 2013, 14, 169.	2.9	14

#	Article	IF	CITATIONS
307	HIV multiâ€drug resistance at firstâ€line antiretroviral failure and subsequent virological response in Asia. Journal of the International AIDS Society, 2014, 17, 19053.	1.2	14
308	Assortative sexual mixing patterns in male–female and male–male partnerships in Melbourne, Australia: implications for HIV and sexually transmissible infection transmission. Sexual Health, 2016, 13, 451.	0.4	14
309	HIV and Aging: Demographic Change in the Asia-Pacific Region. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e146-e148.	0.9	14
310	Rates and Factors Associated with Major Modifications to First-Line Combination Antiretroviral Therapy: Results from the Asia-Pacific Region. PLoS ONE, 2013, 8, e64902.	1.1	14
311	Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy. Antiviral Therapy, 2002, 7, 271-281.	0.6	14
312	Centralized Assessment of Dual-Energy X-ray Absorptiometry (DEXA) in Multicenter Studies of HIV-Associated Lipodystrophy. HIV Clinical Trials, 2003, 4, 45-49.	2.0	13
313	Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. HIV Medicine, 2007, 8, 46-54.	1.0	13
314	Association Between ALT Level and the Rate of Cardio/Cerebrovascular Events in HIV-Positive Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 456-463.	0.9	13
315	Factors Associated with Participation and Attrition in a Longitudinal Study of Bacterial Vaginosis in Australian Women Who Have Sex with Women. PLoS ONE, 2014, 9, e113452.	1.1	13
316	Relationship between CD4 cell count and serious long-term complications among HIV-positive individuals. Current Opinion in HIV and AIDS, 2014, 9, 63-71.	1.5	13
317	Limited Evolution of HIV Antiretroviral Drug Resistance-Associated Mutations During the Performance of Drug Resistance Testing. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 32, 57-61.	0.9	12
318	Predictors and survival in hepatitis Bâ€related hepatocellular carcinoma in New South Wales, Australia. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 436-442.	1.4	12
319	Improving chlamydia knowledge should lead to increased chlamydia testing among Australian general practitioners: a cross-sectional study of chlamydia testing uptake in general practice. BMC Infectious Diseases, 2014, 14, 584.	1.3	12
320	Lower life expectancy among people with an <scp>HCV</scp> notification: a populationâ€based linkage study. Journal of Viral Hepatitis, 2014, 21, e10-8.	1.0	12
321	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. Journal of the National Cancer Institute, 2018, 110, 598-607.	3.0	12
322	Prevalence and determinants of inappropriate antibiotic dispensing at private drug retail outlets in urban and rural areas of Indonesia: a mixed methods study. BMJ Global Health, 2021, 6, e004993.	2.0	12
323	Modelling HIV incidence in gay men: increased treatment, unsafe sex and sexually transmissible infections. Aids, 2002, 16, 499-501.	1.0	12
324	High Viral Fitness during Acute HIV-1 Infection. PLoS ONE, 2010, 5, e12631.	1.1	12

#	Article	IF	CITATIONS
325	Cardiovascular Disease and Cardiovascular Disease Risk in HIV-Positive Populations in the Asian Region. Open AIDS Journal, 2017, 11, 52-66.	0.1	12
326	Epidemiology of hepatitis C virus infection in Australia. Australian Family Physician, 2003, 32, 796-8.	0.5	12
327	Time trends in HIV infection among pregnant women in Europe. Aids, 1998, 12, 211-215.	1.0	11
328	CD4 Cell Responses to Combination Antiretroviral Therapy in Patients Starting Therapy at High CD4 Cell Counts. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 72-79.	0.9	11
329	Improving Oral Human Papillomavirus Detection Using Toothbrush Sampling in HIV-Positive Men Who Have Sex with Men. Journal of Clinical Microbiology, 2014, 52, 2206-2209.	1.8	11
330	Effects of unplanned treatment interruptions on <scp>HIV</scp> treatment failure – results from <scp>TAHOD</scp> . Tropical Medicine and International Health, 2016, 21, 662-674.	1.0	11
331	Attrition and Mortality of Children Receiving Antiretroviral Treatment through the Universal Coverage Health Program in Thailand. Journal of Pediatrics, 2017, 188, 210-216.e1.	0.9	11
332	Strategies to improve control of sexually transmissible infections in remote Australian Aboriginal communities: a stepped-wedge, cluster-randomised trial. The Lancet Global Health, 2019, 7, e1553-e1563.	2.9	11
333	Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 Among Human Immunodeficiency Virus–positive Gay and Bisexual Men?. Clinical Infectious Diseases, 2020, 70, 106-113.	2.9	11
334	HIV Lipodystrophy Case Definition using Artificial Neural Network Modelling. Antiviral Therapy, 2003, 8, 435-441.	0.6	11
335	Ageâ€specific HIV incidence among homosexually active men in Australia. Medical Journal of Australia, 1996, 164, 715-718.	0.8	10
336	Evolution of CD4+ T Cell Count in HIV-1-Infected Adults Receiving Antiretroviral Therapy with Sustained Long-Term Virological Suppression. AIDS Research and Human Retroviruses, 2009, 25, 569-576.	0.5	10
337	The Significance of HIV â€`Blips' in Resource-Limited Settings: Is It the Same? Analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD). PLoS ONE, 2014, 9, e86122.	1.1	10
338	Temporal trends of time to antiretroviral treatment initiation, interruption and modification: examination of patients diagnosed with advanced HIV in Australia. Journal of the International AIDS Society, 2015, 18, 19463.	1.2	10
339	Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007–2010) – TASER-S. AIDS Research and Therapy, 2015, 12, 3.	0.7	10
340	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. Aids, 2016, 30, 1583-1596.	1.0	10
341	Hospitalization for Anxiety and Mood Disorders in HIV-Infected and -Uninfected Gay and Bisexual Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 589-597.	0.9	10
342	Gender differences in the use of cardiovascular interventions in <scp>HIV</scp> â€positive persons; the D:A:D Study. Journal of the International AIDS Society, 2018, 21, e25083.	1.2	10

#	Article	IF	CITATIONS
343	HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme. BMC Public Health, 2019, 19, 13.	1.2	10
344	A Randomized Trial of Nelfinavir, Ritonavir, or Delavirdine in Combination with Saquinavir-SGC and Stavudine in Treatment-Experienced HIV-1-Infected Patients. HIV Clinical Trials, 2001, 2, 97-107.	2.0	9
345	Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data. HIV Medicine, 2003, 4, 332-337.	1.0	9
346	A feasible method for linkage studies avoiding clerical review: linkage of the national HIV/AIDS surveillance databases with the National Death Index in Australia. Australian and New Zealand Journal of Public Health, 2007, 31, 308-312.	0.8	9
347	Dietary Intake in HIV-Infected Men with Lipodystrophy: Relationships with Body Composition, Visceral Fat, Lipid, Glucose and Adipokine Metabolism. Current HIV Research, 2009, 7, 456-461.	0.2	9
348	Subsidized optimal ART for HIV-positive temporary residents of Australia improves virological outcomes: results from the Australian HIV Observational Database Temporary Residents Access Study. Journal of the International AIDS Society, 2015, 18, 19392.	1.2	9
349	Clinical and demographic factors associated with low viral load in early untreated <scp>HIV</scp> infection in the <scp>INSIGHT S</scp> trategic <scp>T</scp> iming of <scp>AntiRetroviral T</scp> reatment (<scp>START</scp>) trial. HIV Medicine, 2015, 16, 37-45.	1.0	9
350	How do outcomes compare between women and men living with HIV in Australia? An observational study. Sexual Health, 2016, 13, 155.	0.4	9
351	Poor record linkage sensitivity biased outcomes in a linked cohort analysis. Journal of Clinical Epidemiology, 2016, 75, 70-77.	2.4	9
352	Patterns of Drug Use and Drug-related Hospital Admissions in HIV-Positive and -Negative Gay and Bisexual Men. AIDS and Behavior, 2016, 20, 2372-2386.	1.4	9
353	People Born in Non–Main English Speaking Countries Are Less Likely to Start HIV Treatment Early in Australia: A National Cohort Analysis, 2014–15. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, e31-e34.	0.9	9
354	Early suboptimal ART adherence was associated with missed clinical visits in HIV-infected patients in Asia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1560-1566.	0.6	9
355	Diabetes, mortality and glucose monitoring rates in the TREAT Asia HIV Observational Database Low Intensity Transfer (TAHODâ€LITE) study. HIV Medicine, 2019, 20, 615-623.	1.0	9
356	Prevalence and Association of Perianal and Intra-Anal Warts with Composite High-Grade Squamous Intraepithelial Lesions Among Gay and Bisexual Men: Baseline Data from the Study of the Prevention of Anal Cancer. AIDS Patient Care and STDs, 2020, 34, 436-443.	1.1	9
357	Treating male partners of women with bacterial vaginosis (StepUp): a protocol for a randomised controlled trial to assess the clinical effectiveness of male partner treatment for reducing the risk of BV recurrence. BMC Infectious Diseases, 2020, 20, 834.	1.3	9
358	Determining standardized causes of death of infants, children, and adolescents living with HIV in Asia. Aids, 2020, 34, 1527-1537.	1.0	9
359	Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study. Clinical Infectious Diseases, 2021, 73, 2037-2044.	2.9	9
360	Time trends in cancer incidence in Australian people living with HIV between 1982 and 2012. HIV Medicine, 2022, 23, 134-145.	1.0	9

#	Article	IF	CITATIONS
361	Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antiviral Therapy, 2006, 11, 179-86.	0.6	9
362	Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals. Aids, 2012, 26, 1707-1717.	1.0	8
363	Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection. Vaccine, 2013, 31, 1931-1936.	1.7	8
364	High Rates of Late HIV Diagnosis Among People Who Inject Drugs Compared to Men Who Have Sex with Men and Heterosexual Men and Women in Australia. AIDS and Behavior, 2013, 17, 235-241.	1.4	8
365	Improving the clinical prediction of detrusor overactivity by utilizing additional symptoms and signs to overactive bladder symptoms alone. International Urogynecology Journal, 2014, 25, 1115-1120.	0.7	8
366	Testing for HIV among men who have sex with men needs a paradigm shift in Australia, given the minimal increase between 2003 and 2013 in Melbourne, Australia. Sexual Health, 2015, 12, 373.	0.4	8
367	Tenofovir-Based Antiretroviral Therapy in HBV–HIV Coinfection: Results from the TREAT Asia HIV Observational Database. Antiviral Therapy, 2016, 21, 27-35.	0.6	8
368	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, e110-e119.	0.9	8
369	Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?. Aids, 2016, 30, 1629-1637.	1.0	8
370	Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003–2013: TREAT Asia HIV Observational Database Low Intensity Transfer. International Journal of STD and AIDS, 2017, 28, 1282-1291.	0.5	8
371	Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000â€2014). Hepatology Communications, 2017, 1, 736-747.	2.0	8
372	Loss to follow-up and Associated Factors of Patients in the National AIDS Program in Thailand. Antiviral Therapy, 2018, 23, 529-538.	0.6	8
373	Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Journal of Infectious Diseases, 2019, 220, 1629-1634.	1.9	8
374	ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 456-462.	0.9	8
375	Cardiovascular disease and diabetes in <scp>HIV</scp> â€positive and HIVâ€negative gay and bisexual men over the age of 55 years in Australia: insights from the Australian Positive & Peers Longevity Evaluation Study. HIV Medicine, 2019, 20, 121-130.	1.0	8
376	Cardiovascular disease among people living with HIV in Brazil. Tropical Medicine and International Health, 2020, 25, 886-896.	1.0	8
377	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS ONE, 2020, 15, e0243625.	1.1	8
378	HIV disease progression in Australia in the time of combination antiretroviral therapies. Medical Journal of Australia, 1998, 169, 469-72.	0.8	8

#	Article	IF	CITATIONS
379	Risk of variant <scp>Creutzfeldt–Jakob</scp> disease transmission by blood transfusion in Australia. Vox Sanguinis, 2022, 117, 1016-1026.	0.7	8
380	Estimation of cumulative HIV incidence in Australia, based on national case reporting. Australian and New Zealand Journal of Public Health, 1996, 20, 215-217.	0.8	7
381	Prognosis of Kaposi's sarcoma as an initial and later AIDS associated illness. Annals of Oncology, 1997, 8, 871-875.	0.6	7
382	Baseline Antiretroviral Drug Susceptibility Influences Treatment Response in Patients Receiving Saquinavir-Enhancing Therapy. HIV Clinical Trials, 2001, 2, 445-452.	2.0	7
383	Selective exclusion of treatment arms in multi-arm randomized clinical trials. Statistics in Medicine, 2003, 22, 19-30.	0.8	7
384	Injecting drug use in Australia: needle/syringe programs prove their worth, but hepatitis C still on the increase. Medical Journal of Australia, 2003, 178, 197-198.	0.8	7
385	Evaluation of Subcutaneous Proleukin (Interleukin-2) in a Randomized International Trial (ESPRIT): Geographical and Gender Differences in the Baseline Characteristics of Participants. HIV Clinical Trials, 2006, 7, 70-85.	2.0	7
386	Methods estimating the prevalence of problem drug use. International Journal of Drug Policy, 2006, 17, 154-158.	1.6	7
387	Quilt Plots: A Simple Tool for the Visualisation of Large Epidemiological Data. PLoS ONE, 2014, 9, e85047.	1.1	7
388	High HIV Prevalence and Associated Risk Factors Among Female Sexual Partners of Male Injection Drug Users (MWID) in Ho Chi Minh City, Vietnam. AIDS and Behavior, 2016, 20, 395-404.	1.4	7
389	A pseudo-random patient sampling method evaluated. Journal of Clinical Epidemiology, 2017, 81, 129-139.	2.4	7
390	Characteristics, mortality and outcomes at transition for adolescents with perinatal HIV infection in Asia. Aids, 2018, 32, 1689-1697.	1.0	7
391	Serious clinical events in HIV-positive persons with chronic kidney disease. Aids, 2019, 33, 2173-2188.	1.0	7
392	The longer-term effects of access to HIV self-tests on HIV testing frequency in high-risk gay and bisexual men: follow-up data from a randomised controlled trial. The Lancet Regional Health - Western Pacific, 2021, 14, 100214.	1.3	7
393	The Applicability of Commonly Used Severity of Illness Scores to Tropical Infections in Australia. American Journal of Tropical Medicine and Hygiene, 2021, , .	0.6	7
394	The impact of removing financial incentives and/or audit and feedback on chlamydia testing in general practice: A cluster randomised controlled trial (ACCEPt-able). PLoS Medicine, 2022, 19, e1003858.	3.9	7
395	HIV and aging: an overview of an emerging issue. Sexual Health, 2011, 8, 449.	0.4	6
396	Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort. Hepatology Research, 2012, 42, 1175-1186.	1.8	6

#	Article	IF	CITATIONS
397	Recent Trends in Early Stage Response to Combination Antiretroviral Therapy in Australia. Antiviral Therapy, 2015, 20, 131-139.	0.6	6
398	Preâ€ŧherapy inflammation and coagulation activation and longâ€ŧerm <scp>CD4</scp> count responses to the initiation of antiretroviral therapy. HIV Medicine, 2015, 16, 449-454.	1.0	6
399	Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD). BMC Infectious Diseases, 2015, 15, 326.	1.3	6
400	Molecular diagnosis of bacterial vaginosis: Does adjustment for total bacterial load or human cellular content improve diagnostic performance?. Journal of Microbiological Methods, 2017, 133, 66-68.	0.7	6
401	Attrition and treatment outcomes among adolescents and youths living with HIV in the Thai National AIDS Program. Journal of Virus Eradication, 2019, 5, 33-40.	0.3	6
402	The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. Journal of Infectious Diseases, 2021, 223, 632-637.	1.9	6
403	On the Use of Fractional Polynomial Models to Assess Preventive Aspect of Variables: An Example in Prevention of Mortality Following HIV Infection. International Journal of Preventive Medicine, 2013, 4, 414-9.	0.2	6
404	The seasonality of infections in tropical Far North Queensland, Australia: A 21-year retrospective evaluation of the seasonal patterns of six endemic pathogens. PLOS Global Public Health, 2022, 2, e0000506.	0.5	6
405	Incidence of HIV infection in a cohort of homosexually active men. Australian and New Zealand Journal of Public Health, 1997, 21, 587-589.	0.8	5
406	Does the presenting bladder volume at urodynamics have any diagnostic relevance?. International Urogynecology Journal, 2009, 20, 319-324.	0.7	5
407	High rates of sexually transmissible infections in HIV-positive patients in the Australian HIV Observational Database: a prospective cohort study. Sexual Health, 2014, 11, 291.	0.4	5
408	Moving Away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE) - Agents That Concern Prescribers and Patients: A Feasibility Study and Call for a Trial. PLoS ONE, 2014, 9, e99530.	1.1	5
409	Hospitalisation rates and associated factors in communityâ€based cohorts of <scp>HIV</scp> â€infected and â€uninfected gay and bisexual men. HIV Medicine, 2016, 17, 327-339.	1.0	5
410	Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database. Sexual Health, 2017, 14, 345.	0.4	5
411	Hepatitis C testing and re-testing among people attending sexual health services in Australia, and hepatitis C incidence among people with human immunodeficiency virus: analysis of national sentinel surveillance data. BMC Infectious Diseases, 2017, 17, 740.	1.3	5
412	Impact of replacing cytology with human papillomavirus testing for cervical cancer screening on the prevalence of <i>Trichomonas vaginalis</i> : a modelling study. Sexually Transmitted Infections, 2018, 94, 216-221.	0.8	5
413	Aging of the HIV Population in Australia: A Modeling Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, e115-e116.	0.9	5
414	Funding antiretroviral treatment for HIV-positive temporary residents in Australia prevents transmission and is inexpensive. Sexual Health, 2018, 15, 13.	0.4	5

#	Article	IF	CITATIONS
415	Longâ€ŧerm loss to followâ€up in the <scp>TREAT</scp> Asia <scp>HIV</scp> Observational Database (<scp>TAHOD</scp>). HIV Medicine, 2019, 20, 439-449.	1.0	5
416	Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a costâ€effectiveness analysis. Journal of the International AIDS Society, 2020, 23, e25494.	1.2	5
417	HIV self-testing for men who have sex with men: an implementation trial in Indonesia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2022, 34, 527-534.	0.6	5
418	Costâ€effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. Journal of the International AIDS Society, 2021, 24, e25690.	1.2	5
419	Problems with Publishing Results of Interim Analyses of Randomized Clinical Trials. HIV Clinical Trials, 2000, 1, 30-36.	2.0	4
420	Capturing the paradigm shift in HIV treatment: Changing attitudes in the choice of combination antiretroviral drugs by high HIV caseload Australian GPs (1996-1997). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2000, 12, 41-47.	0.6	4
421	Cardiovascular complications of HIV: an overview of risk and a novel approach to prevention ??? the HIV polypill study. Current Opinion in HIV and AIDS, 2006, 1, 482-487.	1.5	4
422	Causes of death in hepatitis B and C: a methodological issue. Lancet, The, 2007, 370, 1033.	6.3	4
423	Changes in metabolic, inflammatory and coagulation biomarkers after HIV seroconversion – the Health In Men (HIM) Biomarker sub-study. Antiviral Therapy, 2012, 18, 355-359.	0.6	4
424	Relationship Between Hyperglycemia and the Risk of Tuberculosis in Asian HIV-Positive Individuals in the Antiretroviral Therapy Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, e108-e111.	0.9	4
425	The Impact of Wild-Type Reversion on Transmitted Resistance Surveillance. Antiviral Therapy, 2014, 19, 719-722.	0.6	4
426	Can preventive care activities in general practice be sustained when financial incentives and external audit plus feedback are removed? ACCEPt-able: a cluster randomised controlled trial protocol. Implementation Science, 2015, 11, 122.	2.5	4
427	HIV-infection and comorbidities: a complex mix. Lancet HIV,the, 2015, 2, e265-e266.	2.1	4
428	Risk factors associated with incident sexually transmitted infections in <scp>HIV</scp> â€positive patients in the Australian <scp>HIV</scp> Observational Database: a prospective cohort study. HIV Medicine, 2016, 17, 623-630.	1.0	4
429	Identifying factors that lead to the persistence of importedgonorrhoeaestrains: a modelling study. Sexually Transmitted Infections, 2017, 93, 221-225.	0.8	4
430	Associations between serum albumin and serious non-AIDS events among people living with HIV. Aids, 2018, 32, 1837-1848.	1.0	4
431	Incomplete recording of Indigenous identification status under-estimates the prevalence of Indigenous population attending Australian general practices: a cross sectional study. BMC Health Services Research, 2019, 19, 567.	0.9	4
432	Estimation of Potential HIV Transmission Risk in Recent Anal Intercourse Events among Men Who Have Sex with Men and Transgender Women in Bali, Indonesia. Tropical Medicine and Infectious Disease, 2021, 6, 139.	0.9	4

#	Article	IF	CITATIONS
433	A comparison of adjuvant psychological therapy and supportive counselling in patients with cancer. , 1998, 7, 218.		4
434	Weight changes, metabolic syndrome and all ause mortality among Asian adults living with HIV. HIV Medicine, 2022, 23, 274-286.	1.0	4
435	A Note on the Grouping of Surveillance Data When Adjusting for Reporting Delays. American Journal of Epidemiology, 1997, 146, 592-595.	1.6	3
436	Vinblastine Pharmacokinetics in Patients with Non-Small Cell Lung Cancer Given Cisplatin. Cancer Investigation, 1999, 17, 479-485.	0.6	3
437	Mortality in patients with hepatitis B or hepatitis C – Authors' reply. Lancet, The, 2006, 368, 1767.	6.3	3
438	Effect of nucleoside reverse transcriptase inhibitors on CD4 Tâ€cell recovery in HIVâ€1â€infected individuals receiving longâ€term fully suppressive combination antiretroviral therapy. HIV Medicine, 2009, 10, 143-151.	1.0	3
439	Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study. Sexual Health, 2016, 13, 335.	0.4	3
440	The occurrence of Simpson's paradox if site-level effect was ignored inÂthe TREAT Asia HIV Observational Database. Journal of Clinical Epidemiology, 2016, 76, 183-192.	2.4	3
441	The impact of changes in <scp>HIV</scp> management guidelines on time to treatment initiation in Australia. HIV Medicine, 2017, 18, 701-703.	1.0	3
442	The treatment outcomes of antiretroviral substitutions in routine clinical settings in Asia; data from the <scp>TREAT</scp> Asia <scp>HIV</scp> Observational Database (<scp>TAHOD</scp>). Journal of the International AIDS Society, 2017, 20, e25016.	1.2	3
443	Temporal Trends in Co-trimoxazole Use Among Children on Antiretroviral Therapy and the Impact of Co-trimoxazole on Mortality Rates in Children Without Severe Immunodeficiency. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 450-460.	0.6	3
444	Atherosclerotic cardiovascular disease screening and management protocols among adult HIV clinics in Asia. Journal of Virus Eradication, 2020, 6, 11-18.	0.3	3
445	Long-Term High-Dose Acyclovir and AIDS-Related Non-Hodgkins Lymphoma. Clinical Infectious Diseases, 2001, 32, 989-990.	2.9	2
446	Hospitalization rates associated with hepatitis B and HIV co-infection, age and sex in a population-based cohort of people diagnosed with hepatitis C. Epidemiology and Infection, 2011, 139, 1151-1158.	1.0	2
447	Human papillomavirus and head and neck cancers: emerging trends and improving survival. Australian and New Zealand Journal of Public Health, 2012, 36, 195-196.	0.8	2
448	Predictors of Clinical Progression in HIV-1-Infected Adults Initiating Combination Antiretroviral Therapy with Advanced Disease in the Asia-Pacific Region. Journal of the International Association of Providers of AIDS Care, 2013, 12, 270-277.	0.6	2
449	Risk group characteristics and viral transmission clusters in Southâ€East Asian patients infected with human immunodeficiency virusâ€1 (HIVâ€1) circulating recombinant form (CRF) 01_AE and subtype B. Kaohsiung Journal of Medical Sciences, 2015, 31, 445-453.	0.8	2
450	Growing challenges for HIV programmes in Asia: clinic population trends, 2003–2013. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 1243-1254.	0.6	2

#	Article	IF	CITATIONS
451	First-Line Antiretroviral Treatment Outcomes and Durability in HIV-Infected Children Treated Through the Universal Coverage Health Program in Thailand. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 219-225.	0.9	2
452	Reply to: "Direct antiviral agents and risk of HCC: Waiting for Godot― Journal of Hepatology, 2018, 68, 616-617.	1.8	2
453	Patients with HIV and coronary disease: are we meeting national guidelines?. Sexual Health, 2018, 15, 83.	0.4	2
454	Cardiovascular Disease Incidence Projections in the TREAT Asia HIV Observational Database (TAHOD). Antiviral Therapy, 2019, 24, 271-279.	0.6	2
455	Intra-cerebral haemorrhage but not neurodegenerative disease appears over-represented in deaths of Australian cadaveric pituitary hormone recipients. Journal of Clinical Neuroscience, 2020, 81, 78-82.	0.8	2
456	Comorbidity Medications Are Dispensed to More People Receiving Antiretroviral Therapy for HIV Compared with the General Population in Australia. AIDS Research and Human Retroviruses, 2020, 36, 291-296.	0.5	2
457	The comparative ability of commonly used disease severity scores to predict death or a requirement for ICU care in patients hospitalised with possible sepsis in Yangon, Myanmar. International Journal of Infectious Diseases, 2021, 104, 543-550.	1.5	2
458	An expanded HIV care cascade: ART uptake, viral load suppression and comorbidity monitoring among adults living with HIV in Asia. Antiviral Therapy, 2021, 25, 275-285.	0.6	2
459	Triple class experience after initiation of combination antiretroviral treatment in Australia: survival and projections. Sexual Health, 2011, 8, 295.	0.4	2
460	Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region. Journal of Antivirals & Antiretrovirals, 2009, 01, 028-035.	0.1	2
461	Impact of Testing Strategies to Combat a Major Syphilis Outbreak Among Australian Aboriginal and Torres Strait Islander Peoples: A Mathematical Modeling Study. Open Forum Infectious Diseases, 2022, 9, ofac119.	0.4	2
462	Author's Reply: Survival analysis of randomized clinical trials adjusted for patients who switch treatments by M. G. Law and J. M. Kaldor,Statistics in Medicine,15, 2069-2076 (1996). Statistics in Medicine, 1997, 16, 2620-2621.	0.8	1
463	Reply to DiNubile. Clinical Infectious Diseases, 2009, 49, 811-812.	2.9	1
464	Predictors and Outcomes of HIV-Infected Antiretroviral-Naive Patients With Discordant Responses to Combination Antiretroviral Treatment in Asian and Australian Populations: Results From APHOD. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, e13-e15.	0.9	1
465	Disproportionate Impact of Combination Antiretroviral Therapy on AIDS Incidence in Australia: Results from a Modified Back-projection Model. AIDS and Behavior, 2012, 16, 360-367.	1.4	1
466	The association of HPV-16 seropositivity and natural immunity to reinfection: insights from compartmental models. BMC Infectious Diseases, 2013, 13, 83.	1.3	1
467	HIV Viral Suppression in TREAT Asia HIV Observational Database Enrolled Adults on Antiretroviral Therapy at the Social Health Clinic, the National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia. Antiviral Therapy, 2016, 21, 725-730.	0.6	1
468	Reply to: "â€~Who killed JR': Chronic hepatitis C or alcohol use disorders?― Journal of Hepatology, 2018, 68, 1099-1100.	1.8	1

#	Article	IF	CITATIONS
469	Supplemental Trichomonas vaginalis testing is required to maintain control following a transition from Pap smear to HPV DNA testing for cervical screening: a mathematical modelling study. Sexually Transmitted Infections, 2020, 96, 76-78.	0.8	1
470	Factors Associated With and Characteristic of HIV/Tuberculosis Co-Infection: A Retrospective Analysis of SECOND-LINE Clinical Trial Participants. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 720-729.	0.9	1
471	Treatment modification after second-line failure among people living with HIV in the Asia-Pacific. Antiviral Therapy, 2021, 25, 377-387.	0.6	1
472	Clinical characteristics of overseas-born men who have sex with men (MSM) in the AHOD cohort and implications for clinical practice. Sexually Transmitted Infections, 2020, 96, 469-470.	0.8	1
473	Is the clinical course of HIV infection changing?. BMJ: British Medical Journal, 1997, 315, 1236-1236.	2.4	1
474	The use of back projection to estimate HIV prevalence among pregnant women in Australia. Pediatric AIDS and HIV Infection, 1996, 7, 331-6.	0.1	1
475	The response to COVID-19 among drug retail outlets in Indonesia: A cross-sectional survey of knowledge, attitudes, and practices. The Lancet Regional Health - Western Pacific, 2022, 22, 100420.	1.3	1
476	Sample size calculations for within-patient comparisons with a binary or survival endpoint. Contemporary Clinical Trials, 1996, 17, 221-225.	2.0	0
477	Response from the authors. Australian and New Zealand Journal of Public Health, 2006, 30, 189.	0.8	0
478	HIV transmission under highly active antiretroviral therapy – Authors' reply. Lancet, The, 2008, 372, 1807.	6.3	0
479	Prospective evidence that HIV lipoatrophy and visceral adiposity are partially independent processes. Open Access Journal of Clinical Trials, 0, , 1.	1.5	0
480	Comparison of central and local HIV-1 RNA quantification from two international clinical trials. Aids, 2014, 28, 2480-2483.	1.0	0
481	A Clinical Prediction Tool for Targeted Pre-antiretroviral Therapy Creatinine Testing Applied to the TREAT Asia HIV Observational Database Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, e131-e133.	0.9	0
482	Could point-of-care testing be effective for reducing the prevalence of trichomoniasis in remote Aboriginal communities?. Sexual Health, 2014, 11, 370.	0.4	0
483	Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings. AIDS Research and Therapy, 2017, 14, 27.	0.7	0
484	Use and Outcomes of Antiretroviral Monotherapy and Treatment Interruption in Adolescents With Perinatal HIV Infection in Asia. Journal of Adolescent Health, 2019, 65, 651-659.	1.2	0
485	Reply to: "Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis― Journal of Hepatology, 2019, 71, 1254-1255.	1.8	0
486	PS-SiZer map to investigate significant features of body-weight profile changes in HIV infected patients in the IeDEA Collaboration. PLoS ONE, 2020, 15, e0220165.	1.1	0

#	Article	IF	CITATIONS
487	Trends in Follow-Up Visits Among People Living With HIV: Results From the TREAT Asia and Australian HIV Observational Databases. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 70-78.	0.9	о
488	Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis. PLoS ONE, 2021, 16, e0256926.	1.1	0
489	Country review: Australia. , 2008, , 85-102.		0
490	Modelling response strategies for controlling gonorrhoea outbreaks in men who have sex with men in Australia. PLoS Computational Biology, 2021, 17, e1009385.	1.5	0